Results 111 to 120 of about 22,177 (184)

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression. [PDF]

open access: yesEinstein (Sao Paulo)
Amarger CD   +8 more
europepmc   +1 more source

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry. [PDF]

open access: yesOncologist
Passiglia F   +45 more
europepmc   +1 more source

SMC6 expression & outcome of breast cancer. [PDF]

open access: yesIndian J Med Res
Mangone FRR   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy